BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

412 related articles for article (PubMed ID: 9503098)

  • 21. Evaluation of immunotherapy by nasal antigen challenge.
    Cengizlier R; Saraçlar Y; Tomaç N
    J Otolaryngol; 1999 Aug; 28(4):185-8. PubMed ID: 10461254
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical evaluation of lumiward immunoassay system for detection of specific IgE associated with allergic rhinitis.
    Yamada K; Ohashi Y; Tanaka A; Kakinoki Y; Washio Y; Hayashi M; Kishimoto K; Nakai Y
    Acta Otolaryngol Suppl; 1998; 538():169-77. PubMed ID: 9879417
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Topical nasal immunotherapy. Immunologic response of IgE in nasal secretion after immunotherapy with Dermatophagoides pteronyssinus.
    Martín Mateos MA; Monferrer R; Muñoz López F
    Allergol Immunopathol (Madr); 1990; 18(4):223-8. PubMed ID: 2264553
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Observation on the effect of the dust mite sublingual immunotherapy for allergic rhinitis].
    Du X; Shu C; Xu G; Ma M; Song H
    Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2012 Apr; 26(8):372-3. PubMed ID: 22730824
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effects of short-term immunotherapy using molecular standardized grass and rye allergens compared with symptomatic drug treatment on rhinoconjunctivitis symptoms, skin sensitivity, and specific nasal reactivity.
    Klimek L; Mewes T; Wolf H; Hansen I; Schnitker J; Mann WJ
    Otolaryngol Head Neck Surg; 2005 Oct; 133(4):538-43. PubMed ID: 16213926
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of sublingual immunotherapy in patients with rhinitis and asthma due to house dust mite. A double-blind study.
    Tari MG; Mancino M; Monti G
    Allergol Immunopathol (Madr); 1990; 18(5):277-84. PubMed ID: 2097894
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Specific nasal provocation test with powder allergen.
    Salzano FA
    Allergy; 1997; 52(33 Suppl):32-5. PubMed ID: 9188946
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical efficacy and safety of local nasal immunotherapy.
    Andri L; Senna GE; Dama AR
    Allergy; 1997; 52(33 Suppl):36-9. PubMed ID: 9188947
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A new method of administration of topical nasal extracts. Immunoaerosol therapy.
    Sánchez Palacios A; Sánchez Palacios MA; García Marrero JA
    Allergol Immunopathol (Madr); 1992; 20(4):135-8. PubMed ID: 1485592
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The early effect of specific immunotherapy on lymphocyte response to PHA and allergens in atopic patients with allergic rhinitis.
    Kinikli G; Tülek N; Sentürk T; Turgay M; Tutkak H; Duman M; Tokgöz G
    Allergol Immunopathol (Madr); 1996; 24(2):65-9. PubMed ID: 8933891
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Monitoring the efficacy of immunotherapy by symptom scores and the skin prick test in patients with allergic rhinitis].
    Akbaş Y; Saatçi MR
    Kulak Burun Bogaz Ihtis Derg; 2003 Jun; 10(6):221-5. PubMed ID: 13679688
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term follow-up of nasal immunotherapy to Parietaria: clinical and local immunological effects.
    Passalacqua G; Albano M; Pronzato C; Riccio AM; Scordamaglia A; Falagiani P; Canonica GW
    Clin Exp Allergy; 1997 Aug; 27(8):904-8. PubMed ID: 9291287
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Non-specific hyperreactivity before and after nasal specific immunotherapy.
    Filiaci F; Zambetti G; Romeo R; Ciofalo A; Luce M; Germano F
    Allergol Immunopathol (Madr); 1999; 27(1):24-8. PubMed ID: 10217669
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Double-blind, placebo-controlled evaluation of grass pollen specific immunotherapy with oral drops administered sublingually or supralingually.
    Panzner P; Petrás M; Sýkora T; Lesná I
    Respir Med; 2008 Sep; 102(9):1296-304. PubMed ID: 18585908
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis.
    Frew AJ; Powell RJ; Corrigan CJ; Durham SR;
    J Allergy Clin Immunol; 2006 Feb; 117(2):319-25. PubMed ID: 16461133
    [TBL] [Abstract][Full Text] [Related]  

  • 36. How to design and evaluate randomized controlled trials in immunotherapy for allergic rhinitis: an ARIA-GA(2) LEN statement.
    Bousquet J; Schünemann HJ; Bousquet PJ; Bachert C; Canonica GW; Casale TB; Demoly P; Durham S; Carlsen KH; Malling HJ; Passalacqua G; Simons FE; Anto J; Baena-Cagnani CE; Bergmann KC; Bieber T; Briggs AH; Brozek J; Calderon MA; Dahl R; Devillier P; Gerth van Wijk R; Howarth P; Larenas D; Papadopoulos NG; Schmid-Grendelmeier P; Zuberbier T
    Allergy; 2011 Jun; 66(6):765-74. PubMed ID: 21496059
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The type of sensitizing allergen can affect the evolution of respiratory allergy.
    Marogna M; Massolo A; Berra D; Zanon P; Chiodini E; Canonica GW; Passalacqua G
    Allergy; 2006 Oct; 61(10):1209-15. PubMed ID: 16942571
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nasal treatment with a microemulsion reduces allergen challenge-induced symptoms and signs of allergic rhinitis.
    Andersson M; Greiff L; Wollmer P
    Acta Otolaryngol; 2008 Jun; 128(6):666-9. PubMed ID: 18568502
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Randomized double-blind controlled study with sublingual carbamylated allergoid immunotherapy in mild rhinitis due to mites.
    Passalacqua G; Pasquali M; Ariano R; Lombardi C; Giardini A; Baiardini I; Majani G; Falagiani P; Bruno M; Canonica GW
    Allergy; 2006 Jul; 61(7):849-54. PubMed ID: 16792583
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Oral immunotherapy in oculorhinitis from Gramineae].
    Pacor ML; Biasi D; Carletto A; Maleknia T; Lunardi C
    Recenti Prog Med; 1996 Jan; 87(1):4-6. PubMed ID: 8711254
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.